×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Japan Depression Screening Mental Health Market

ID: MRFR/HC/54518-HCR
200 Pages
Rahul Gotadki
October 2025

Japan Depression Screening Mental Health Market Research Report By Indication (Major Depressive Disorder, Anxiety Distress, Bipolar Disorder, Psychotic Disorders, Others), By Diagnosis (Psychological Tests, Blood Tests, Pharmacogenomic Testing, Others) and By End User (Hospitals and Clinics, Home-based, Research and Academic Institutes)- Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Japan Depression Screening Mental Health Market Infographic
Purchase Options

Japan Depression Screening Mental Health Market Summary

As per MRFR analysis, the Japan depression screening market size was estimated at 27.39 USD Million in 2024. The Japan depression screening-mental-health market is projected to grow from 28.79 USD Million in 2025 to 47.23 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.08% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Japan The depression screening market is experiencing a transformative shift towards technology integration and preventive care.

  • Technology integration in screening processes is reshaping mental health assessments.
  • Government initiatives and policy support are fostering a more robust framework for mental health services.
  • Preventive mental health care is gaining traction, especially among younger demographics.
  • Rising awareness of mental health issues and increased investment in mental health infrastructure are key drivers of market growth.

Market Size & Forecast

2024 Market Size 27.39 (USD Million)
2035 Market Size 47.23 (USD Million)
CAGR (2025 - 2035) 5.08%

Major Players

UnitedHealth Group (US), Anthem (US), Cigna (US), Kaiser Permanente (US), CVS Health (US), Teladoc Health (US), LivaNova (GB), Mindstrong Health (US), Talkspace (US)

Japan Depression Screening Mental Health Market Trends

The depression screening-mental-health market is currently experiencing notable shifts, driven by an increasing awareness of mental health issues among the population. In Japan, the government has been actively promoting mental health initiatives, which has led to a rise in the demand for screening tools and services. This heightened focus on mental well-being is reflected in various sectors, including healthcare and education, where mental health screenings are becoming more integrated into routine practices. Furthermore, the stigma surrounding mental health appears to be gradually diminishing, encouraging individuals to seek help and participate in screening programs. Moreover, technological advancements are playing a crucial role in shaping the landscape of the depression screening-mental-health market. Digital platforms and mobile applications are emerging as effective tools for screening and monitoring mental health conditions. These innovations not only enhance accessibility but also provide users with personalized resources and support. As a result, the market is likely to witness a surge in the adoption of these technologies, which could further facilitate early detection and intervention for depression and related disorders. Overall, the current trends suggest a promising future for the depression screening-mental-health market, with ongoing efforts to improve mental health awareness and access to screening services.

Integration of Technology in Screening Processes

The incorporation of digital tools and mobile applications is transforming the way depression screening is conducted. These technologies offer convenient access to screening resources, enabling individuals to assess their mental health from the comfort of their homes. This trend is likely to enhance engagement and participation in screening programs.

Government Initiatives and Policy Support

The Japanese government actively promotes mental health awareness through various initiatives. This support is fostering a more favorable environment for the development and implementation of depression screening services, which may lead to increased accessibility and utilization.

Focus on Preventive Mental Health Care

There is a growing emphasis on preventive measures in mental health care, particularly in the context of depression. This trend indicates a shift towards early detection and intervention, with screening becoming a critical component of overall health strategies.

Japan Depression Screening Mental Health Market Drivers

Aging Population and Mental Health Needs

Japan's demographic shift towards an aging population presents a unique challenge and opportunity for the depression screening-mental-health market. With over 28% of the population aged 65 and older, there is a significant need for mental health services tailored to older adults. This demographic is particularly vulnerable to depression, often exacerbated by isolation and health issues. As a result, healthcare providers are increasingly focusing on screening and intervention strategies for this age group. The market is likely to grow as more resources are allocated to address the mental health needs of the elderly.

Rising Awareness of Mental Health Issues

In Japan, there is a growing awareness regarding mental health issues, particularly depression. depression screening services. Public campaigns and educational programs have been instrumental in reducing stigma associated with mental health, encouraging individuals to seek help. According to recent surveys, approximately 30% of the population acknowledges experiencing mental health challenges, which indicates a substantial market potential. As more people recognize the importance of mental health, the depression screening-mental-health market is expected to expand, with increased participation in screening programs and consultations.

Technological Advancements in Screening Tools

Technological advancements are playing a crucial role in the evolution of the depression screening-mental-health market in Japan. The development of digital tools and mobile applications for mental health assessment is gaining traction, allowing for more accessible and efficient screening processes. These innovations can potentially reach a broader audience, particularly younger populations who are more inclined to use technology for health-related issues. As these tools become more sophisticated and user-friendly, they are likely to enhance the overall effectiveness of screening efforts, thereby contributing to the growth of the market.

Integration of Mental Health into Primary Care

Integrating mental health services into primary care settings is increasingly prevalent in Japan. This approach facilitates early detection and intervention for depression, thereby enhancing the effectiveness of the depression screening-mental-health market. By training primary care providers to recognize and address mental health issues, the likelihood of individuals receiving timely screenings increases. Studies suggest that integrated care models can improve patient outcomes and reduce healthcare costs, making this a promising direction for the market. As more healthcare systems adopt this model, the demand for screening services is expected to rise.

Increased Investment in Mental Health Infrastructure

The Japanese government has recognized the necessity of improving mental health infrastructure, which is expected to bolster the depression screening-mental-health market. Recent budget allocations indicate a commitment to enhancing mental health services, with an increase of approximately 15% in funding for mental health programs. This investment aims to expand access to screening and treatment options, particularly in underserved areas. As facilities improve and more professionals enter the field, the market is poised for growth, providing better resources for individuals seeking mental health support.

Market Segment Insights

By Indication: Major Depressive Disorder (Largest) vs. Bipolar Disorder (Fastest-Growing)

In the Japan depression screening-mental-health market, the distribution of market share among various indications reveals that Major Depressive Disorder holds the largest share. This condition is perceived as the most prevalent, garnering significant attention and resources for treatment and screening. Following this, Anxiety Distress and Bipolar Disorder are also notable, but they account for comparatively smaller portions of the market, reflecting diverse treatment needs across the population. Growth trends show a significant increase in the awareness and diagnosis of Bipolar Disorder, positioning it as the fastest-growing segment. The rising recognition of mental health issues, along with ongoing public health campaigns on the importance of early detection and treatment, are driving this growth. Furthermore, societal changes and reduced stigma around mental health contribute to the increasing prevalence of diagnoses across these indications.

Major Depressive Disorder: Dominant vs. Bipolar Disorder: Emerging

Major Depressive Disorder is characterized by persistent feelings of sadness and loss of interest, affecting millions and necessitating extensive screening and intervention efforts. This segment remains dominant in the Japan depression screening-mental-health market, underlined by the availability of diverse treatment modalities ranging from therapy to medication. On the other hand, Bipolar Disorder, marked by mood swings between depressive and manic episodes, is emerging swiftly due to growing awareness and diagnostic advancements. The momentum for Bipolar Disorder reflects a shift in focus toward comprehensive mental health care, where early identification is essential, positioning it as a critical area for further development in healthcare strategies.

By Diagnosis: Psychological Tests (Largest) vs. Blood Tests (Fastest-Growing)

In the Japan depression screening-mental-health market, Psychological Tests hold the largest share, reflecting their established role in diagnosing depression. These tests encompass a range of standardized assessments that effectively identify symptoms and severity levels of depression, contributing to their dominance. Meanwhile, Blood Tests are gaining ground and are recognized as the fastest-growing segment due to advancements in technology that offer more precise diagnostics through biological markers. The growth trends in the diagnosis segment are driven primarily by innovations in testing methodologies and increasing awareness of mental health issues. The rising prevalence of depression has prompted healthcare providers to seek out effective and rapid screening tools, making Psychological Tests indispensable. Simultaneously, Blood Tests are becoming an attractive option, as they provide objective data that can complement traditional assessments, enhancing overall diagnostic accuracy and patient outcomes.

Psychological Tests: Dominant vs. Blood Tests: Emerging

Psychological Tests are the dominant segment in the diagnosis landscape, characterized by their long-standing acceptance in clinical practice. They offer comprehensive evaluations of mental health, enabling clinicians to assess patients systematically. These tests include scales like the Beck Depression Inventory and Hamilton Rating Scale, known for their reliability. In contrast, Blood Tests are the emerging segment, driven by growing interest in biomarkers for mental health. These tests promise to revolutionize diagnostics by providing measurable physiological indicators of depression, potentially reducing the stigma associated with psychiatric assessments. As technology advances, the integration of Blood Tests into routine screening could lead to more personalized treatment plans, improving patient engagement and adherence.

By End User: Hospitals and Clinics (Largest) vs. Home-based (Fastest-Growing)

In the Japan depression screening-mental-health market, the distribution of market share among various end users reveals that hospitals and clinics hold a significant portion, making them the largest segment. This is primarily due to their established infrastructure for mental health services and the specialist attention they can offer to individuals suffering from depression. Home-based solutions, on the other hand, are rapidly gaining traction, especially post-pandemic, as they offer convenience and accessibility for patients who prefer receiving care in a familiar environment. Growth trends indicate a robust shift towards home-based screening solutions, driven by technological advancements and increased awareness about mental health issues. The pandemic brought forward a need for innovative solutions, enabling remote screenings and consultations, making this segment the fastest-growing. Additionally, research and academic institutes play a crucial role by contributing to evidence-based practices and developing new methodologies, thus supporting the overall growth of the market.

Hospitals and Clinics (Dominant) vs. Home-based (Emerging)

Hospitals and clinics represent the dominant force in the mental health segment, offering comprehensive services, professional care, and advanced diagnostic tools necessary for effective depression screening. Their established position is characterized by sophisticated facilities, trained personnel, and direct access to a variety of mental health resources. In contrast, the home-based segment is emerging as a viable alternative, reflecting a shift in consumer preferences towards convenience and flexibility. Home-based solutions leverage technology to facilitate at-home screening and virtual consultations, making mental health care more accessible. This innovation caters to individuals who may be reluctant to visit physical locations for treatment, thus playing a pivotal role in expanding the reach of mental health services.

Get more detailed insights about Japan Depression Screening Mental Health Market

Key Players and Competitive Insights

The depression screening-mental-health market in Japan is characterized by a dynamic competitive landscape, driven by increasing awareness of mental health issues and the growing demand for accessible screening solutions. Key players such as UnitedHealth Group (US), Cigna (US), and Teladoc Health (US) are strategically positioning themselves through digital transformation and innovative service offerings. UnitedHealth Group (US) focuses on integrating technology into its mental health services, enhancing patient engagement and accessibility. Meanwhile, Cigna (US) emphasizes partnerships with local healthcare providers to expand its reach and improve service delivery. Teladoc Health (US) leverages telehealth solutions to provide remote mental health screenings, catering to a population increasingly seeking convenience in healthcare access. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and patient-centric solutions.

The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing services to meet regional needs and optimizing supply chains to enhance service delivery. The influence of major players is significant, as they set benchmarks for quality and accessibility, thereby shaping consumer expectations and competitive dynamics.

In October 2025, UnitedHealth Group (US) announced a partnership with a leading Japanese telehealth provider to enhance its mental health screening capabilities. This strategic move is likely to bolster its market presence in Japan, allowing for a more tailored approach to local mental health needs. By integrating local expertise with its technological resources, UnitedHealth Group (US) aims to improve patient outcomes and streamline service delivery.

In September 2025, Cigna (US) launched a new mental health initiative focused on workplace wellness, targeting corporate clients in Japan. This initiative underscores Cigna's commitment to addressing mental health in the workplace, which is increasingly recognized as a critical component of employee well-being. By aligning its services with corporate wellness programs, Cigna (US) positions itself as a leader in the corporate mental health space, potentially increasing its client base and enhancing service utilization.

In August 2025, Teladoc Health (US) expanded its mental health services by introducing AI-driven screening tools designed to provide personalized assessments. This innovation reflects a broader trend towards integrating artificial intelligence in healthcare, aiming to enhance the accuracy and efficiency of mental health screenings. By adopting such technologies, Teladoc Health (US) not only improves its service offerings but also sets a precedent for future developments in the mental health sector.

As of November 2025, current trends in the depression screening-mental-health market include a pronounced shift towards digitalization and the integration of AI technologies. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and enhancing service delivery. The focus appears to be shifting from traditional price-based competition to a model that prioritizes technological advancement, service quality, and supply chain reliability. This evolution suggests that companies will need to differentiate themselves through innovative solutions and strategic partnerships to remain competitive in the rapidly changing market.

Key Companies in the Japan Depression Screening Mental Health Market market include

Industry Developments

In recent months, the Japan Depression Screening Mental Health Market has seen significant activity, shaped by ongoing efforts to enhance mental health initiatives in the country. Recent developments include advancements in digital mental health solutions by companies like Fujitsu and LINE Corporation, focusing on integrating Artificial Intelligence into their screening processes. Notable growth has been observed in the market valuation of companies such as Astellas Pharma and Eisai, reflecting a rising demand for mental health services amid a growing awareness of depression and mental health issues.

Moreover, in July 2023, Takeda Pharmaceutical announced a strategic partnership with iTHRIVE, aiming to broaden access to depression screening tools. 

The past couple of years also witnessed major events, including Mitsubishi Tanabe Pharma’s emphasis on Research and Development in depression treatment available in Japan, further underlining the increasing focus on mental health solutions. The Japanese government is also actively promoting better mental health policies, fostering an environment conducive to growth in this market segment. Overall, the combination of corporate activities and public health initiatives is driving evolution within the Japan Depression Screening Mental Health Market.

Future Outlook

Japan Depression Screening Mental Health Market Future Outlook

The Depression Screening Mental Health Market in Japan is projected to grow at a 5.08% CAGR from 2024 to 2035, driven by increasing awareness and technological advancements.

New opportunities lie in:

  • Integration of AI-driven diagnostic tools in clinical settings.
  • Expansion of telehealth services for remote patient monitoring.
  • Development of personalized treatment plans using genetic profiling.

By 2035, the market is expected to achieve substantial growth and innovation.

Market Segmentation

Japan Depression Screening Mental Health Market End User Outlook

  • Hospitals and Clinics
  • Home-based
  • Research and Academic Institutes

Japan Depression Screening Mental Health Market Diagnosis Outlook

  • Psychological Tests
  • Blood Tests
  • Pharmacogenomic Testing
  • Others

Japan Depression Screening Mental Health Market Indication Outlook

  • Major Depressive Disorder
  • Anxiety Distress
  • Bipolar Disorder
  • Psychotic Disorders
  • Others

Report Scope

MARKET SIZE 2024 27.39(USD Million)
MARKET SIZE 2025 28.79(USD Million)
MARKET SIZE 2035 47.23(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.08% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled UnitedHealth Group (US), Anthem (US), Cigna (US), Kaiser Permanente (US), CVS Health (US), Teladoc Health (US), LivaNova (GB), Mindstrong Health (US), Talkspace (US)
Segments Covered Indication, Diagnosis, End User
Key Market Opportunities Integration of digital tools for enhanced depression screening and personalized mental health interventions.
Key Market Dynamics Rising demand for digital mental health solutions drives innovation in depression screening methodologies and technologies.
Countries Covered Japan

Leave a Comment

FAQs

What is the expected market size of the Japan Depression Screening Mental Health Market in 2024?

The Japan Depression Screening Mental Health Market is expected to be valued at 36.5 million USD in 2024.

What will the market size be by 2035?

By 2035, the Japan Depression Screening Mental Health Market is projected to reach 71.0 million USD.

What is the compound annual growth rate (CAGR) for the Japan Depression Screening Mental Health Market from 2025 to 2035?

The market is expected to grow at a CAGR of 6.235% from 2025 to 2035.

Which indication has the largest market share in 2024 within the Japan Depression Screening Mental Health Market?

The Major Depressive Disorder indication holds the largest market share valued at 12.5 million USD in 2024.

What are the projected market sizes for Anxiety Distress from 2024 to 2035?

The market size for Anxiety Distress is projected to grow from 10.0 million USD in 2024 to 18.5 million USD by 2035.

Who are the major players in the Japan Depression Screening Mental Health Market?

Key players in the market include Mizuho Financial Group, Mitsubishi Tanabe Pharma, and Takeda Pharmaceutical among others.

What is the anticipated market size for Bipolar Disorder in 2035?

The market size for Bipolar Disorder is expected to reach 13.5 million USD in 2035.

What challenges are anticipated in the Japan Depression Screening Mental Health Market?

Challenges in the market may arise from regulatory hurdles and the stigma associated with mental health treatment.

Is there an emerging trend within the Japan Depression Screening Mental Health Market?

An emerging trend includes the increased use of digital health tools for patient screening and monitoring.

What is the growth expectation for Psychotic Disorders in the Japan Depression Screening Mental Health Market by 2035?

The market for Psychotic Disorders is expected to grow from 5.0 million USD in 2024 to 10.5 million USD by 2035.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions